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inTRODUCTiOn
Colorectal cancer (CRC) is the third most common cancer worldwide, with an estimated 1.4 million 
new cases and almost 700,000 related deaths globally each year (1). In Australia, CRC is the second 
most commonly reported cancer and second most common cause of cancer-related death (2). 
Moreover, Australia has the fourth highest incidence of CRC for men and fifth highest for women 
internationally (3, 4). Incidence rates of CRC have at least doubled in many countries since the mid-
1970s (5–7), although trends vary across countries with stabilizing or declining rates in more recent 
years reported in Western Europe and the United States (US), respectively. This trend is reversed 
for high-income nations that have recently made the transition from low-income economies (8, 9).
In the majority of cases, CRC develops from non-malignant precursor adenomatous colonic 
polyps (adenomas) (10), with the overall adenoma burden dependent on the number, size, vil-
losity, dysplasia grade, and location of adenomas in the colon. Importantly, the average interval 
from adenoma appearance to development of CRC is >10 years (11), and the removal of adenomas 
reduces CRC incidence and mortality (12, 13). This affords an excellent opportunity for early detec-
tion through screening and regular colonoscopic surveillance, and the condition meets the World 
Health Organization criteria for diseases suited to screening (14). Patients with prior adenoma are 
therefore recommended to undergo regular surveillance colonoscopy (15). Increased surveillance, in 
addition to advances in surgical and adjuvant therapy (16), has been shown to reduce CRC incidence 
and increase median 5-year survival for CRC from 55.0% in the early 1980s to 65.3% by 2005 (16).
Lifetime prevalence of adenoma is 40–50% (17), however, the majority of adenomas never 
develop into malignant neoplasms and only 4–5% of the population eventually develop CRC (18). 
Consequently, simply identifying the presence of adenomas does not represent the most efficient 
approach for making informed recommendations for the need and timing of follow-up colonoscopic 
surveillance and the overall adenoma burden and specific adenoma characteristics should be fac-
tored into clinical decision making (12, 13).
USE OF COLOnOSCOpY FOR CRC DETECTiOn
Although some population-based screening programs exist employing fecal occult blood testing 
(FOBT), colonoscopy remains the “gold-standard” for detection of CRC and precursor adenomas 
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(19). However, others have suggested that colonoscopy is overused 
as a primary screening and surveillance tool leading to sizable 
increases in the rates of colonoscopy in many countries (20–22).
In Australia, rising usage of colonoscopy has been seen for 
over two decades, with Medicare claims for the procedure 
increasing by 250% in the last 10  years (23). This increase has 
occurred simultaneously with increased capacity within the pri-
vate hospital sector (24). Given the current trajectory, and when 
considered with population aging and the promotion of earlier 
screening, it is estimated that over 1 million colonoscopies will 
be performed annually by 2020 in Australia (population 24 mil-
lion) (25). Similar relative trends have been reported elsewhere, 
with greater absolute increases, in countries such as the US (26). 
Such demand is not sustainable for most health systems, both 
in terms of provider capacity and health-care costs, estimated to 
be in the multiple billions of dollars annually in western nations 
(27). Furthermore, if projected increases in demand are realized, 
access to this service will be compromised, especially in public 
health systems. Already in Australia waiting times for colonos-
copy exceeding 250 days are not uncommon (28, 29).
RiSK STRATiFiCATiOn AppROACHES  
TO CRC DETECTiOn AnD pREVEnTiOn
Researchers, including our team, have previously called for greater 
consideration of personalized risk stratification approaches to 
primary screening for CRC (30); however, less consideration has 
been given to the potential benefits of such approaches for ongo-
ing surveillance. Targeting colonoscopy to patients who stand to 
benefit most (i.e., those at higher risk of CRC) through robust 
risk stratification would reduce the burden of colonoscopies 
to both patients and the health system, while maintaining the 
preventive benefits of surveillance colonoscopy. Such targeting 
could reduce burden for lower-risk patients, who are less likely 
to benefit and reduce waiting times for high-risk patients who 
require more regular surveillance. In addition, as most adenoma 
patients face a lifetime of burdensome colonoscopies with its 
associated bowel preparation and procedural risks, targeting 
surveillance to high-risk patients would also likely increase 
compliance with recommended follow-up colonoscopy intervals, 
which is often poor; only 36% of patients comply with clinical 
guideline recommended intervals for surveillance colonoscopy in 
Australia (31). Moreover, with increasing incidence in CRC seen 
in younger age groups (32, 33), especially those under eligibility 
age thresholds for FOBT programs (34), and differential surveil-
lance colonoscopy compliance based on patient insurance status 
(35), risk stratification holds additional benefits for particular 
patient groups.
The literature on risk stratification for CRC prevention 
primarily incorporates factors such as family history and soci-
odemographics (age, sex, and socioeconomic status) with some 
models also incorporating genetic variants associated with CRC 
susceptibility (36). Where surveillance colonoscopy is consid-
ered, adenoma number, size, villosity, and dysplasia grade at the 
most recent investigation are the more common determinants 
for recommending future surveillance intervals, whereas other 
factors including proximal or distal adenoma location, and the 
total adenoma burden over time are often overlooked as risk 
factors for future CRC.
inCORpORATinG DATA FROM MULTipLE 
pRiOR COLOnOSCOpiES
The cumulative burden of prior colorectal adenoma has almost 
exclusively been omitted from risk stratification approaches for 
surveillance colonoscopy, often due to unavailability of data. 
Most research in this area has only incorporated data from the 
most recent colonoscopy. However, it is likely that the risk of 
adenoma recurrence or development of CRC is modified by 
prior adenoma and/or changes in adenoma characteristics over 
time. Therefore, risk increases are likely conditional on adenoma 
characteristics from multiple earlier examinations rather than 
just the most recent investigation.
To date, there has been little published work which has con-
sidered longitudinal colonoscopy history for risk prediction of 
CRC. Estimates from a relatively small study (n < 3,000) of Dutch 
patients investigated predictive ability of baseline colonoscopy on 
adenoma burden for up to two subsequent colonoscopies (37). 
The authors reported that optimizing timing of colonoscopy 
surveillance by incorporating multiple risk factors could result 
in 20% fewer surveillance colonoscopies being required annu-
ally, while maintaining the same level of effectiveness in terms of 
cancer detection and life-years gained (37). Three other studies 
have reported on rates of advanced adenoma or CRC incorporat-
ing up to two surveillance colonoscopies (38–40), although, as 
commented by the US Multi-Society Task Force on Colorectal 
Cancer (41), all have important limitations possibly resulting in 
selection bias. Despite these weaknesses, findings were consistent 
across these studies suggesting that accounting for longitudinal 
colonoscopy history could provide important information for 
CRC risk prediction. While these results are encouraging, there 
is currently a complete lack of findings in the literature beyond 
the second surveillance colonoscopy. Consequently, the extent to 
which adenoma burden over a patient’s life mediates future CRC 
risk is largely unknown.
Due to the lack of empirical data in this area, recommended 
intervals for follow-up colonoscopy in most national clinical 
guidelines, such as those in the US, UK, Australia, and Europe 
(15, 41–43), are almost exclusively based on results of the latest 
examination alone. Consequently, existing international guide-
lines are arguably a compromise that may not accurately define 
optimal intervals for repeat surveillance in patients with detected 
adenomas over multiple prior colonoscopies.
In Australia, clinical guidelines advocate that a risk assessment 
combining the results at baseline and at least one repeat surveil-
lance examination may be a superior tool for CRC prediction than 
reliance on findings at the latest examination (15). However, there 
is no guidance provided on how to use that information other 
than a general statement that endoscopists should be encouraged 
to consider previous colonoscopy findings. The authors of the 
Australian Clinical Guidelines for Colonoscopy Surveillance 
recognize this limitation and recommend further research to 
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determine CRC risk after a series of surveillance examinations, 
stratified by risk parameters of the baseline adenomas (15). This 
has also been highlighted as an important area in an Australian 
gap analysis (44).
OppORTUniTiES in THE CURREnT DATA 
EnViROnMEnT
The emergence of whole-population data linkage systems in 
many countries has afforded the opportunity to combine com-
prehensive data from a range of health service data collections 
for large samples over decades. Such linkage systems provide a 
powerful resource for conducting longitudinal research on large 
or even entire populations and have benefits for minimizing, if 
not overcoming, limitations due to sample size, selection bias, 
response or recall bias, loss-to-follow-up, and ascertainment of 
accurate health service exposure and outcome measures. The use 
of such data has become commonplace in health research (45), 
and linkage of whole-population non-consented service data for 
research purposes is an accepted ethical approach (46).
Data from such linkage systems could also lay the foundation 
for more robust risk stratification of populations, incorporating 
a wide range of sociodemographic, clinical, and genetic factors 
depending on the data available to be linked. Linkage systems, 
such as the Western Australian Data Linkage System (47), use 
widely accepted probabilistic-matching techniques and already 
have capacity to link decades of cancer registry, inpatient, pathol-
ogy, and mortality data, combined with the ability to genealogi-
cally link patients at the individual-level to derive familial history 
of disease and “genetic” risk factors. Such data provide a unique 
platform to investigate different risk stratification models for 
CRC detection through colonoscopy surveillance. Moreover, 
due to the extensive observation periods that can be investigated, 
these systems provide the opportunity to incorporate data based 
on findings over multiple surveillance colonoscopies, which 
have been omitted from the literature to date but are likely 
an important component for precision targeting of ongoing 
surveillance windows. Additional linkage to National Bowel 
Cancer Screening Program records and large cohort studies, 
which may provide information on a range of health behaviors 
not routinely captured in administrative data such as smoking, 
alcohol consumption, diet, and physical activity would further 
enhance the ability to precisely stratify CRC risk and tailor 
appropriate follow-up intervals. The lack of such behavioral risk 
factor information, rarely captured in administrative data, is a 
potential limitation and arguably does not allow all risk factors 
to be considered in risk stratification models. However, available 
administrative data do allow targeting of factors most relevant to 
guideline-based decision making in this area. Furthermore, the 
approach proposed in this paper would still provide an advance 
on existing risk-stratification models as a result of accounting for 
the cumulative burden of prior colorectal adenoma which has 
been omitted from risk stratification approaches to CRC screen-
ing and surveillance to date.
In addition, when combined with the availability of tools such 
as MISCAN-Colon, a well-established microsimulation model for 
CRC (48, 49), evaluation of the cost-effectiveness of different risk 
stratification models for informing timing of ongoing follow-up 
colonoscopy for CRC is possible. Such work can also be tailored 
to jurisdictional-specific settings and precedents exist for the 
adaption of the MISCAN-Colon model to local settings, such as 
the Australian-specific variant of MISCAN-Colon (50).
COnCLUSiOn
Whole-population data linkage systems are uniquely placed to 
allow robust longitudinal investigation to develop risk stratifica-
tion models for CRC surveillance. Systems would require the 
capacity to link data collections comprising demographic, cancer 
registry, hospital inpatient, pathology, mortality, and genealogical 
factors over multiple decades at the whole-of-population level. 
The ability to link additional behavioral risk factor data (e.g., 
smoking, alcohol consumption, and dietary intake) from sources 
such as large cohort studies would also add value. The linking 
of such data collections would allow relevant risk factors to be 
accounted for in risk stratification models, including the incorpo-
ration of complete colonoscopy history and adenoma burden over 
time, which represents a potentially important modifying factor 
for cancer risk but is currently not included in risk modeling for 
recurrent adenoma of CRC.
In addition to providing greater precision with patient risk 
profiling, estimates can be used in cost-effectiveness analyses 
to determine optimal colonoscopy surveillance intervals for 
patients at different levels of cancer risk. This could reduce costs 
to the health system without a reduction in the number of CRCs 
that surveillance colonoscopy prevents. Such information also 
has capacity to support rational decisions concerning the best 
strategy for repeat surveillance via colonoscopy for patients 
at both low and high risk for CRC and reduce excessive delays 
for surveillance colonoscopy, especially for high-risk patients. 
Moreover, it creates an evidence-base for recommendations that 
would be immediately implementable in clinical practice with 
the potential to influence national colonoscopy surveillance 
guidelines.
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